Clinical Trials on Hepatitis, Chronic in Australia

Total 1504 results

AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Hepatitis C, Chronic

France, Spain, United States, Germany, Canada, Australia, Austria, United Kingdom, Puerto Rico, Italy
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

Belgium, United States, Israel, China, Australia, Germany, Russian Federation, Ukraine, United Kingdom, Poland, Bulgaria, Italy
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Hoffmann-La Roche

Completed

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China, Korea, Republic of, Taiwan, Germany, United States, Singapore, Switzerland, Canada, Puerto Rico, Thailand, Israel, France, New Zealand, Poland, United Kingdom, Brazil, Australia
Bristol-Myers Squibb

No longer available

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Netherlands, Austria, Germany, United Kingdom, Sweden
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

Hepatitis B, Chronic

Australia, New Zealand, Singapore, Thailand, Taiwan, China, Bulgaria, Hong Kong
Gilead Sciences

Completed

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

Chronic Hepatitis B

France, Canada, Spain, Germany, Italy, United States, New Zealand, Australia, Czech Republic, Bulgaria, Turkey, Poland, Greece, Netherlands, United Kingdom
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Gilead Sciences

Completed

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

Chronic Hepatitis B

Australia, France, Canada, Spain, Turkey, Italy, United States, Greece, Germany, New Zealand, Czech Republic, Bulgaria, Poland, United Kingdom, Netherlands
Fremantle Hospital and Health Service

Completed

In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

Hepatitis C

Australia
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, Germany, United States, Canada, Austria, Puerto Rico
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Bristol-Myers Squibb

Completed

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Argentina, France, Italy, Korea, Republic of, Taiwan, United States, Spain, Australia, Brazil
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
GlaxoSmithKline

Recruiting

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) (B-Well 2)

Chronic Hepatitis B | Hepatitis B, Chronic

United States, Australia, France, Germany, Italy, Spain, Taiwan, Mexico, United Kingdom, Greece, Korea, Republic of, China, Argentina, Brazil, Bulgaria, Japan, Poland, Hungary, Philippines, Singapore, India, Turkey, Thailand, Canada, Ro... and more
Pharmasset

Terminated

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus (QUASH2)

Hepatitis B | Chronic Hepatitis

United States, Canada, China, Argentina, Taiwan, Spain, Puerto Rico, Australia, Greece, Thailand, United Kingdom
Hoffmann-La Roche

Completed

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

Hepatitis C, Chronic

Australia, Canada, Mexico, New Zealand, Thailand, Argentina
Hoffmann-La Roche

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, Thailand, Brazil, Russian Federation, Australia
Hoffmann-La Roche

Completed

A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B

Hepatitis B, Chronic

Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, France, Thailand, Russian Federation, Australia, Italy
Hoffmann-La Roche

Terminated

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Hepatitis C, Chronic

France, United States, Canada, New Zealand, Spain, Germany, United Kingdom, Australia, Italy, Brazil, Mexico, Slovakia, Poland, Puerto Rico, Austria
Hoffmann-La Roche

Completed

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Hepatitis C, Chronic

United States, New Zealand, Germany, Australia, Poland
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Pharmasset

Terminated

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus (QUASH 1)

Hepatitis B | Chronic Hepatitis

United States, Canada, Argentina, Taiwan, Spain, Puerto Rico, Australia, Greece, Thailand, United Kingdom, Brazil, China
AbbVie

Completed

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Hepatitis C

Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Hoffmann-La Roche

Completed

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

Germany, Austria, Hungary, Romania, Spain, Poland
Kirby Institute

Recruiting

Australian Hepatitis and Risk Survey in Prisons (AusHep)

HIV Infections | Hepatitis B | Hepatitis C

Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)

Hepatitis D, Chronic

France, Taiwan, Italy, Germany, Japan, Spain, Russian Federation, Turkey, United Kingdom, Australia, Sweden, United States, New Zealand, China, Brazil
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Kirby Institute
The University of New South Wales

Completed

Australian Trial in Acute Hepatitis C Recall Study (ATAHC Recall)

Acute Hepatitis C

Australia
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Gilead Sciences

Completed

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

Hepatitis C, Chronic

United States, Spain, Australia, Netherlands, Italy, New Zealand, Germany, United Kingdom, France, Sweden, Canada, Estonia, Poland, Puerto Rico, Austria, Czechia
Vaxine Pty Ltd
Flinders Medical Centre

Completed

Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine

Exposure to Hepatitis B Virus

Australia
Gilead Sciences

Completed

Gilead Sustained Virologic Response (SVR) Registry

Hepatitis C, Chronic

United States, Spain, Netherlands, France, Australia, Canada, Italy, Germany, New Zealand, Belgium, Sweden, United Kingdom, Estonia, Puerto Rico, Austria, Poland, Czechia
Hoffmann-La Roche

Completed

HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

Hepatitis C, Chronic

France, Greece, Austria, Turkey, United Arab Emirates, Brazil, Italy, Indonesia
Novartis Pharmaceuticals

Terminated

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Hepatitis C, Chronic

Romania, Italy, Germany, Belgium, Spain, Australia, Thailand, United States, Hungary, Taiwan, Poland, Canada, Puerto Rico, Vietnam, Korea, Republic of, India
Syneos Health
F-star Therapeutics, Inc.

Completed

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Hepatitis C Infection

Australia, New Zealand
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Macfarlane Burnet Institute for Medical Research...
Department of Health and Human Services

Recruiting

Link Hepatitis C Notifications to Treatment in Tasmania

Hepatitis C

Australia
ZymoGenetics
Bristol-Myers Squibb

Unknown

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)

Hepatitis C, Chronic

Australia, France, Poland, United States, Spain, Germany, Romania, Canada, Austria, Italy, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Bayside Health
National Institutes of Health (NIH); Monash Medical Centre

Unknown

Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)

HIV Infections | HIV-hepatitis Co-infection

Australia
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden

Clinical Trials on Hepatitis, Chronic in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations